Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL23AP76 is a processed pseudogene derived from the ribosomal protein L23a (RPL23A) gene family[3][8]. Pseudogenes are segments of DNA similar to known genes but typically lack the ability to produce functional proteins due to mutations or loss of essential regulatory elements. RPL23AP76 is located on chromosome 14 (GRCh37: 14,851,058–14,851,515)[8]. While ribosomal proteins and their pseudogenes may be found throughout the genome, and some pseudogenes might have regulatory or evolutionary roles, there is no evidence that RPL23AP76 has any functional, diagnostic, or therapeutic importance in humans. It is not an enzyme, receptor, transporter, ion channel, or typical drug target. No phenotypic, disease, or clinical associations are attributed to this specific pseudogene in the literature or databases[3][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L23a pseudogene 76 (RPL23AP76).